BioSpace News Archive

Israel-based Moebius Medical today announced that the US Food and Drug administration (FDA) has cleared their Investigational New Drug (IND) application to initiate a global multi-center Phase IIb clinical trial of MM-II, a novel candidate for the treatment of pain in knee osteoarthritis (OA).

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that children in the open-label long-term extension of the Phase 3 study of vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP), maintained an increase in Annual Growth Velocity (AGV) through the second year of continuous treatment.

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its breast cancer vaccine.

Emulate, Inc., a leading provider of advanced in vitro models, today unveiled the Emulate Brain-Chip, which is designed for neuroscience researchers investigating neuroinflammatory disease and for drug developers seeking to improve drug discovery for neurodegenerative diseases such as Alzheimer’s and Parkinson’s.

Hoth (NASDAQ: HOTH) has a partnership agreement with Zylö Therapeutics Inc.,to co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosus (CLE), a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life.

DURECT Corporation (Nasdaq: DRRX) today announced that it will participate in the forthcoming H.C. Wainwright BioConnect 2021 Conference and Annual LifeSci Advisors Corporate Access Event. Both conferences w

Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from the pilot field effectiveness study of its monoclonal antibody against tumour necrosis factor alpha (anti-TNFα antibody) for canine inflammatory bowel disease (IBD).

Cognoptix, a leading healthcare company for early-stage detection of Alzheimer’s disease (AD), announces its co-founder, Lee Goldstein, M.D., Ph.D. has joined Cognoptix’s Scientific Advisory Board, serving as Co-Chair, and the company’s Board of Directors.

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to market its QuickVue® SARS Antigen test,

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will present virtually at the 39th Annual J.P. Morgan Healthcare Conference.